So that's a really good question. And I think I will ask you to answer the next because I am really interested in the Chinese perspective of this. We have been using DV for about 3 years in clinical trials. At my institution, we’ve treated about 50 patients, but that's probably more than any other European or American institutions. It is not that widely used outside of clinical trials. My experience of the drug is active and it looks similar to EV. Whether we will ever do a trial comparing them two, I don't know. I don't think we will. I'd like to answer that question. My feeling is the toxic profile is different. My feeling is there's less skin toxity, but my feeling is there might be slightly more fatigue. That's my experience. 

The question in Europe and the United States will be around the biomarker a little bit. If you don't need to use the biomarker and it's not clearly better. People say, why not just give EV-P to everyone? EV+Pembro is easy. You don't need to measure HER2. The clinical community in Europe and the United States is currently not routinely using biomarkers to select patients for urothelial cancer and is not routinely measuring HER-2. So unless the results of the Chinese randomize phase Ⅲ and the global randomize phase Ⅲ come up with results in the hazard ratio of zero point three and zero point four, it's unlikely it will displace EV-P. There is one exception to that，in the HER2(+++)  population，the very high HER2 expressors，there is a chance that the efficacy is much better. We don't know that yet I don't know we, but is that worth the case? And the hazard ratios in the HER2(+++)  were in the zero point two and zero point three. I think then the United states and Europe start using biomarkers in this place. Thank you.